feburic治疗痛风效果

(Febuxostat) is a new non-purine xanthine oxidase (XO) selective inhibitor that works by reducing blood urate concentration. It is completely absorbed orally and has high bioavailability. Food and antacids have no significant impact on its absorption. In April 2008, the European EMEA approved the marketing of febuxostat tablets. In February 2009, the US FDA approved the marketing of febuxostat tablets. It is the first new anti-gout drug approved by the FDA in the past 40 years. How effective is feburic (febuxostat) in treating ventilation?

A multicenter, double-blind, randomized phase II clinical study evaluated the safety and efficacy of feburic (febuxostat) in gout. A total of 136 male and 17 female gout patients were randomly assigned to receive placebo or this product (40, 80 or 120 mg/d). After 4 weeks, tests found that the serum uric acid concentration of patients in each dose group of this product was significantly lower than before treatment, with an average reduction of 37% and 44% in each group from low to high dose, respectively. and 59%, while patients in the placebo group only decreased by 2%; the vast majority of patients persisted in completing the trial. The incidence of adverse reactions in the feburic (febuxostat) and placebo groups was similar, and most of these adverse reactions were mild and self-limiting. Common ones include diarrhea, pain, back pain, headache and joint pain.

The starting dose of feburic (febuxostat) is 40 mg once daily. If the blood uric acid level is still not less than 6 mg/dl (approximately 360 μmol/L) after 2 weeks, it is recommended that the dose be increased to 80 mg once a day. Food and antacid effects do not need to be considered when administering the drug. Patients with mild or moderate hepatic insufficiency (Child-Pugh class A, B) do not need to adjust the dosage. Patients with severe hepatic insufficiency (Child-Pugh class C) should use feburic (febuxostat) with caution.

Pediatric Use: The safety and effectiveness of this product in treating patients under 18 years of age have not been established.

Elderly patients: No dosage adjustment is required for elderly patients. According to foreign literature reports, in clinical studies of feburic (febuxostat), people aged 65 and over accounted for 16% of the total number of subjects, and people aged 75 and over accounted for 4%. Comparing subjects of different age groups, there is no clinically significant difference in effectiveness and safety, but it cannot be ruled out that some elderly patients are more sensitive to this product. After multiple oral administrations of (febuxostat) to elderly subjects (65 years and above), Cmax and AUC24 were similar to those of young subjects (18 to 40 years old).